LSTA vs. VXRT, CLYM, JSPR, ADAG, XBIT, BYSI, CTOR, JMAC, ZURA, and OCX
Should you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Vaxart (VXRT), Climb Bio (CLYM), Jasper Therapeutics (JSPR), Adagene (ADAG), XBiotech (XBIT), BeyondSpring (BYSI), Citius Oncology (CTOR), Maxpro Capital Acquisition (JMAC), Zura Bio (ZURA), and OncoCyte (OCX). These companies are all part of the "pharmaceutical products" industry.
Lisata Therapeutics vs. Its Competitors
Lisata Therapeutics (NASDAQ:LSTA) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 499.76%. Vaxart has a consensus target price of $3.00, indicating a potential upside of 327.35%. Given Lisata Therapeutics' higher probable upside, research analysts plainly believe Lisata Therapeutics is more favorable than Vaxart.
Vaxart received 297 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 93.33% of users gave Lisata Therapeutics an outperform vote while only 65.47% of users gave Vaxart an outperform vote.
Lisata Therapeutics has a net margin of 0.00% compared to Vaxart's net margin of -431.61%. Lisata Therapeutics' return on equity of -51.19% beat Vaxart's return on equity.
In the previous week, Vaxart had 4 more articles in the media than Lisata Therapeutics. MarketBeat recorded 6 mentions for Vaxart and 2 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 0.94 beat Vaxart's score of 0.72 indicating that Lisata Therapeutics is being referred to more favorably in the media.
Lisata Therapeutics has higher earnings, but lower revenue than Vaxart. Vaxart is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 18.0% of Vaxart shares are owned by institutional investors. 9.6% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Lisata Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Vaxart has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
Summary
Lisata Therapeutics beats Vaxart on 10 of the 17 factors compared between the two stocks.
Get Lisata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lisata Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LSTA) was last updated on 6/15/2025 by MarketBeat.com Staff
Buy LSTA Stock Free LSTA Stock Alerts